Multicenter HIV and hepatitis B seroprevalence study.

J Emerg Med

Division of Emergency Medicine, Oregon Health Sciences University, Portland 97201-3098.

Published: August 1990

AI Article Synopsis

Article Abstract

Prior single institutional investigations have found unrecognized HIV seroprevalence in emergency department (ED) patients to range from 0.38% to 4%. A prospective, anonymous study of HIV and hepatitis B (HB) seroprevalence was performed on excess serum of all ED patients over two 48-hour periods in May and August, 1988, from 7 hospitals in the Portland metropolitan area. Demographics were known for 338/444 (76%) of patients. Forty-six percent were male, 85% white, with a median age group of 30-39 years. Ambulance transport, trauma, external blood, presentations requiring ED procedure(s), and acuity resulting in ICU admission were present on 21%, 7%, 10%, 34%, and 14% of patients, respectively. Two of 444 (.45%) patients were HIV +, one previously undiagnosed. Fifty-five of the 444 (12%) and 3 of 444 (0.6%) samples were positive for HBcAB and HBsAG respectively. Risk factor assessment was possible on 180/444 (40%) patients. HBcAB seroprevalence correlated with race (P less than 0.01), IV drug use (P less than 0.0001), and hospital location, (P less than 0.006) but were sensitive in detecting only 14%, 18%, and 38%, respectively, of HBcAB+ patients. HBcAB was not associated with the following factors: sex, area of residence, presence of blood externally, trauma, acuity of illness, ED procedures, or mode of transport. This data strongly support the use of universal body fluid precautions. Hepatitis B poses a significant and distinct risk to all emergency care providers. HB vaccination should be strongly advocated for all ED health care workers (HCWs). Emergency medicine multicenter studies are both desirable and feasible.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0736-4679(90)90001-cDOI Listing

Publication Analysis

Top Keywords

hiv hepatitis
8
hepatitis seroprevalence
8
patients hbcab
8
patients
7
multicenter hiv
4
seroprevalence
4
seroprevalence study
4
study prior
4
prior single
4
single institutional
4

Similar Publications

Eight years after WHO adopted a resolution to eliminate hepatitis B by the year 2030, the disease remains a global public health concern, with vertical transmission of HBV being a major obstacle to this goal. Our study aimed to determine the HBV infection status of pregnant women in South Africa at a national level to evaluate the risk of vertical transmission and provide evidence for public health decision-making. We conducted HBsAg testing on 1,942 HIV-uninfected and 2,312 HIV-infected pregnant women from South Africa's public health sector in 2017, followed by HBeAg testing on HBsAg-positive samples.

View Article and Find Full Text PDF

Prenatal syphilis and adverse pregnancy outcomes in women with HIV receiving ART in Brazil: a population-based study.

Lancet Reg Health Am

November 2024

Ministry of Health - Brazil, Department of Surveillance, Prevention and Control of STIs, AIDS, and Viral Hepatitis, SRTVN Quadra 701, Lote D, Edifício PO700 - 5º Andar, CEP: 70719-040, Brasília/DF, Brazil.

Background: We aimed to examine factors associated with prenatal syphilis, including prenatal care, and pregnancy outcomes of pregnant women with HIV in Brazil.

Methods: Retrospective data were gathered from a national cohort of Brazilian women with HIV on antiretroviral therapy who became pregnant between January 2015 and May 2018. Prenatal syphilis was defined by clinical diagnoses with treatment or any positive syphilis laboratory result between 30 days before conception and pregnancy conclusion.

View Article and Find Full Text PDF

Background: Tecovirimat, an antiviral treatment for smallpox, was approved as a treatment for mpox by the European Medicines Agency in January 2022. Approval was granted under "exceptional circumstances" based on effectiveness found in pre-clinical challenge studies in animals and safety studies in humans showing minimal side effects. As clinical efficacy studies are still ongoing, there is currently limited information with regard to the acceptability of tecovirimat to treat mpox.

View Article and Find Full Text PDF

Drug interactions in HIV patients treated with antivirals for other viral illnesses.

Expert Opin Drug Metab Toxicol

January 2025

Yale School of Medicine, Department of Internal Medicine, Section of Infectious Diseases, New Haven, CT.

Introduction: Background:People with HIV (PWH) have benefited tremendously from effective antiretroviral (ARV) treatments. However, PWH are at increased risk for other viral infections transmitted in the same way as HIV (such as hepatitis C and MPox) or that are opportunistic (e.g.

View Article and Find Full Text PDF

Advancing Ethical Considerations for Data Science in Injury and Violence Prevention.

Public Health Rep

January 2025

Division of Injury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Data science is an emerging field that provides new analytical methods. It incorporates novel data sources (eg, internet data) and methods (eg, machine learning) that offer valuable and timely insights into public health issues, including injury and violence prevention. The objective of this research was to describe ethical considerations for public health data scientists conducting injury and violence prevention-related data science projects to prevent unintended ethical, legal, and social consequences, such as loss of privacy or loss of public trust.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!